Mediven Receives CE Mark for Molecular, Rapid Immunoassay Tests

Jun 08, 2016

|

NEW YORK (GenomeWeb) – Medical Innovation Ventures (Mediven) has received the CE-IVD mark for molecular and rapid tests that facilitate diagnosis for fecal occult blood, pregnancy, dengue, and tuberculosis.

One of the rapid tests, the ProDetect FOB Rapid Test, is a direct binding immunoassay for rapidly and qualitatively detecting the presence of human occult blood in feces. The other rapid pregnancy tests detect the presence of hCG in urine during the early stages of pregnancy.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Testing Less Likely

Women with breast or ovarian cancer living in medically underserved regions of the US are less likely to get recommended BRCA1 or BRCA2 genetic testing, according to a new study.

Three for Immunotherapy

Three immunology researchers are to receive this year's Albany Medical Center Prize in Medicine and Biomedical Research, the Albany Times-Union reports.

This Week in Genome Research

In Genome Research this week: clonal evolution analysis of acute myeloid leukemia, computational pipeline to examine relationships between bacterial pathogens, and more.

Cancer-Fighting Zombies

Elephants may have "re-animated" a pseudogene to help stave off cancer, according to the New York Times.

Main menu